tirzepatide sexual function study libido 🚨 New Research Alert! 🚨 From @sexmedresearch For the first time, a GLP-1/GIP medication (tirzepatide) has been shown to successfully treat Persistent Genital Arousal Disorder (PGAD/GPD) — When GLP-1 Medications Affect Libido:

Therapeutic advances in endocrinology and metabolism , 12, 2042018821989238

It's about managing the full picture

Standard FDA-approved dosing escalation The FDA-approved tirzepatide dosing schedule, used in the SURMOUNT and SURPASS clinical trials, follows this pattern: Weeks 1 to 4: 2.5 mg once weekly (starting dose) Weeks 5 to 8: 5 mg once weekly Weeks 9 to 12: 7.5 mg once weekly (optional increase) Weeks 13 to 16: 10 mg once weekly (optional increase) Weeks 17 to 20: 12.5 mg once weekly (optional increase) Week 21 and beyond: 15 mg once weekly (maximum dose) Each dose increase happens after a minimum of four weeks at the current dose

Prandial options to advance basal insulin glargine therapy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 trial